FDA approves Afinitor for pancreatic NET

Novartis has announced US Food and Drug Administration approval of Afinitor (everolimus) for the treatment of progressive neuroendocrine tumours of pancreatic origin (NET). This is in line with a recommendation from an FDA advisory panel.